Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 381.40
-5.15 (-1.33%)
At close: Jan 23, 2026
Cohance Lifesciences Revenue
Cohance Lifesciences had revenue of 5.56B INR in the quarter ending September 30, 2025, with 115.57% growth. This brings the company's revenue in the last twelve months to 12.11B, up 25.95% year-over-year. In the fiscal year ending March 31, 2025, Cohance Lifesciences had annual revenue of 11.98B with 13.91% growth.
Revenue (ttm)
12.11B
Revenue Growth
+25.95%
P/S Ratio
12.22
Revenue / Employee
9.99M
Employees
1,212
Market Cap
148.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 11.98B | 1.46B | 13.91% |
| Mar 31, 2024 | 10.51B | -2.89B | -21.56% |
| Mar 31, 2023 | 13.40B | 201.07M | 1.52% |
| Mar 31, 2022 | 13.20B | 3.11B | 30.75% |
| Mar 31, 2021 | 10.10B | 1.76B | 21.10% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 76.18B |
| Granules India | 48.42B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| FDC Limited | 20.77B |
| Caplin Point Laboratories | 20.42B |
| AstraZeneca Pharma India | 20.06B |
| Sanofi India | 19.33B |
| Viyash Scientific | 16.58B |